| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
|
|
|
|||||||
|
|||||||||
| ||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||||
E-mail contact: bianchi.marco@hsr.it
The receptor for advanced glycation endproducts (RAGE) mediates responses to cell danger and stress. When bound by its many ligands (which include advanced glycation endproducts, certain members of the S100/calgranulin family, extracellular high-mobility group box 1, the integrin Mac-1, amyloid 
-peptide and fibrils), RAGE activates programs responsible for acute and chronic inflammation. RAGE is therefore also involved in cancer progression, diabetes, atherosclerosis, and Alzheimer’s disease. RAGE has several isoforms deriving from alternative splicing, including a soluble form called endogenous secretory RAGE (esRAGE). We show here that most soluble RAGE, either produced by cell lines or present in human blood, is not recognized by an anti-esRAGE antibody. Cells transfected with the cDNA for full-length RAGE, and thus not expressing esRAGE, produce a form of soluble RAGE, cleaved RAGE (cRAGE) that derives from proteolytic cleavage of the membrane-bound molecules and acts as a decoy receptor. By screening chemical inhibitors and genetically modified mouse embryonic fibroblasts (MEFs), we identify the sheddase ADAM10 as a membrane protease responsible for RAGE cleavage. Binding of its ligand HMGB1 promotes RAGE shedding. Our data do not disprove the interpretation that high levels of soluble forms of RAGE protect against chronic inflammation, but rather suggest that they correlate with high levels of ongoing inflammation.—Raucci, A., Cugusi, S., Antonelli, A., Barabino, S. M., Monti, L., Bierhaus, A., Reiss, K., Saftig, P., Bianchi, M. E. A soluble form of the receptor for advanced glycation endproducts (RAGE) is produced by proteolytic cleavage of the membrane-bound form by the sheddase a disintegrin and metalloprotease 10 (ADAM10).
This article has been cited by other articles:
|
|
 |
|
  S. F. Yan, R. Ramasamy, and A. M. Schmidt The RAGE Axis: A Fundamental Mechanism Signaling Danger to the Vulnerable Vasculature Circ. Res., March 19, 2010; 106(5): 842 - 853. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 K. H. J. Gaens, I. Ferreira, C. J. H. van der Kallen, M. M. J. van Greevenbroek, E. E. Blaak, E. J. M. Feskens, J. M. Dekker, G. Nijpels, R. J. Heine, L. M. 't Hart, et al. Association of Polymorphism in the Receptor for Advanced Glycation End Products (RAGE) Gene with Circulating RAGE Levels J. Clin. Endocrinol. Metab., December 1, 2009; 94(12): 5174 - 5180. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H.-L. Xu, F. Vetri, H.-K. Lee, S. Ye, C. Paisansathan, L. Mao, F. Tan, and D. A. Pelligrino Estrogen replacement therapy in diabetic ovariectomized female rats potentiates postischemic leukocyte adhesion in cerebral venules via a RAGE-related process Am J Physiol Heart Circ Physiol, December 1, 2009; 297(6): H2059 - H2067. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 H. Maillard-Lefebvre, E. Boulanger, M. Daroux, C. Gaxatte, B. I. Hudson, and M. Lambert Soluble receptor for advanced glycation end products: a new biomarker in diagnosis and prognosis of chronic inflammatory diseases Rheumatology, October 1, 2009; 48(10): 1190 - 1196. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 R. Ramasamy, S. F. Yan, and A. M. Schmidt RAGE: therapeutic target and biomarker of the inflammatory response--the evidence mounts J. Leukoc. Biol., September 1, 2009; 86(3): 505 - 512. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. S. Buhimschi, M. A. Baumbusch, A. T. Dulay, E. A. Oliver, S. Lee, G. Zhao, V. Bhandari, R. A. Ehrenkranz, C. P. Weiner, J. A. Madri, et al. Characterization of RAGE, HMGB1, and S100{beta} in Inflammation-Induced Preterm Birth and Fetal Tissue Injury Am. J. Pathol., September 1, 2009; 175(3): 958 - 975. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 C. Selvais, H. P. Gaide Chevronnay, P. Lemoine, S. Dedieu, P. Henriet, P. J. Courtoy, E. Marbaix, and H. Emonard Metalloproteinase-Dependent Shedding of Low-Density Lipoprotein Receptor-Related Protein-1 Ectodomain Decreases Endocytic Clearance of Endometrial Matrix Metalloproteinase-2 and -9 at Menstruation Endocrinology, August 1, 2009; 150(8): 3792 - 3799. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 X. Su, M. R. Looney, N. Gupta, and M. A. Matthay Receptor for advanced glycation end-products (RAGE) is an indicator of direct lung injury in models of experimental lung injury Am J Physiol Lung Cell Mol Physiol, July 1, 2009; 297(1): L1 - L5. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 A. Z. Kalea, N. Reiniger, H. Yang, M. Arriero, A. M. Schmidt, and B. I. Hudson Alternative splicing of the murine receptor for advanced glycation end-products (RAGE) gene FASEB J, June 1, 2009; 23(6): 1766 - 1774. [Abstract] [Full Text] [PDF]
|
|
|
|
 |
|
 J. B Lindsey, F. Cipollone, S. M Abdullah, and D. K Mcguire Receptor for advanced glycation end-products (RAGE) and soluble RAGE (sRAGE): cardiovascular implications Diabetes and Vascular Disease Research, January 1, 2009; 6(1): 7 - 14. [Abstract] [PDF]
|
|
|
|
 |
|
 L. Zhang, M. Bukulin, E. Kojro, A. Roth, V. V. Metz, F. Fahrenholz, P. P. Nawroth, A. Bierhaus, and R. Postina Receptor for Advanced Glycation End Products Is Subjected to Protein Ectodomain Shedding by Metalloproteinases J. Biol. Chem., December 19, 2008; 283(51): 35507 - 35516. [Abstract] [Full Text] [PDF]
|
|
| HOME | HELP | FEEDBACK | SUBSCRIPTIONS | ARCHIVE | SEARCH |
